Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease

We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrba, Lukas, Futscher, Bernard W., Oshiro, Marc, Watts, George S., Menashi, Emmanuel, Hu, Charles, Hammad, Hytham, Pennington, Daniel R., Golconda, Umamaheshwari, Gavini, Hemanth, Roe, Denise J., Shroff, Rachna T., Nelson, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864826/
https://www.ncbi.nlm.nih.gov/pubmed/35193708
http://dx.doi.org/10.1186/s13148-022-01246-2
Descripción
Sumario:We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-022-01246-2.

Ejemplares similares